| Financial Highlights | Financial Review | | Management’s Report | Audit Committee’s Report | | Independent Auditors’ Report | Financial Statements | | Notes to Financial Statements | | Directors, Committees, and Officers | | Corporate and Shareholder Information |

	Financial Highlights (Section 1 of 2) Pfizer Inc and Subsidiary Companies
	Year ended December 31     (millions except per share data) 1997 1996 1995 Total revenues $12,504 $11,306 $10,021 Income from continuing operations before provision for taxes on income and minority interests 3,088 2,804 2,299 Provision for taxes on income 865 869 738 Net income 2,213 1,929 1,573 Research and development expenses 1,928 1,684 1,442 Property, plant and equipment additions 943 774 696 Cash dividends paid 881 771 659 Diluted earnings per common share 1.70 1.50 1.25 Cash dividends paid per common share .68 .60 .52 Shareholders’ equity per common share 6.30 5.54 4.45 Weighted average shares — diluted 1,303 1,288 1,259 (thousands) Number of shareholders 87 65 63 Number of employees 49 47 44 All historical share and per share data throughout this report have been restated to reflect the 1997 two-for-one stock split in the form of a 100 percent stock dividend. In addition, earnings per common share and weighted average shares reflect the adoption of Statement of Financial Accounting Standards No. 128, “Earnings per Share.”
	Total Revenues (millions of dollars)	Net Income (millions of dollars)

	Advisory Information for Investors
	Copyright © 1997, 1998 Pfizer Inc All rights reserved.